Does Body Weight Impact Cosentyx Dosing?
Cosentyx (secukinumab) uses fixed dosing regardless of patient weight. Adults receive 300 mg weekly for the first month (two 150 mg subcutaneous injections per dose), then 300 mg every 4 weeks. This contrasts with weight-based drugs like TNF inhibitors (e.g., Humira), where higher weight often requires dose adjustments.[1]
What Clinical Trials Show on Weight and Effectiveness
Pivotal trials for psoriasis, psoriatic arthritis, and ankylosing spondylitis included patients across BMI ranges (18.5–40+ kg/m²). Response rates were consistent: about 80% PASI 75 achievement in psoriasis at week 12, with no significant weight-related drop-off in efficacy.[2] Post-hoc analyses confirmed similar ACR20 responses in psoriatic arthritis for obese (BMI ≥30) vs. normal-weight patients.[3]
Why Might Effectiveness Vary in Heavier Patients?
Obesity can reduce biologic penetration due to higher fat mass and inflammation, potentially lowering peak concentrations. Real-world data shows obese patients (BMI >30) have 10–20% lower response rates to IL-17 inhibitors like Cosentyx vs. normal-weight groups, though still effective (e.g., 60–70% PASI 90).[4] Fixed dosing may underexpose heavier patients; some studies suggest splitting the 300 mg dose into three 100 mg injections improves absorption in obesity.[5]
How Does Cosentyx Compare to Other Biologics by Weight?
| Drug | Dosing Type | Obesity Impact |
|------|-------------|---------------|
| Cosentyx (IL-17) | Fixed | Modest; better than TNFs in obese[6] |
| Stelara (IL-12/23) | Weight-based (<100 kg: 45 mg; ≥100 kg: 90 mg) | Minimal variation[7] |
| Humira (TNF) | Fixed | Larger efficacy drop in BMI >30[8] |
| Skyrizi (IL-23) | Fixed | Similar to Cosentyx; sustained in obesity[9] |
IL-17/23 inhibitors generally hold up better in obesity than TNFs, per head-to-head meta-analyses.[10]
Practical Tips for Heavier Patients
Weight loss improves outcomes across biologics, boosting Cosentyx response by 15–25% in studies combining it with lifestyle changes.[11] No official weight adjustments exist; physicians monitor via PASI/ACR scores and may switch if needed. Pediatric dosing is weight-tiered (15–<60 kg: 75–150 mg).[12]
[1]: Cosentyx Prescribing Information
[2]: Langley RG et al., N Engl J Med 2014
[3]: McInnes IB et al., Ann Rheum Dis 2015
[4]: DrugPatentWatch.com (real-world IL-17 data)
[5]: Papp K et al., J Am Acad Dermatol 2018
[6]: Di Meglio P et al., Nat Rev Rheumatol 2020
[7]: Blauvelt A et al., J Am Acad Dermatol 2017
[8]: Gniadecki R et al., Br J Dermatol 2015
[9]: Reich K et al., Lancet 2017
[10]: Rungapirom N et al., JAMA Dermatol 2021
[11]: Jensen P et al., JAMA Dermatol 2019
[12]: FDA Label Update 2023